TICKERNERD
Menu
BCRXBCRXHealthcare · Drug Manufacturers - Specialty & Generic

BCRX Stock Forecast: BioCryst Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$8.12
−2.05% on the day

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +109.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.1B
Ticker Nerd rank
87 / 100
Median analyst target
$17
Analysts covering
11
Revenue$218.3M+33.6% y/y
Operating income$98.5M
Net income$78.4M
Free cash flow$104.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.5%
1M
−21.5%
YTD
+4.1%
1Y
+0.6%
From 52W high
−26.9%
From 52W low
+30.1%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioCryst Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Volatility
94
Accruals
91
Quality
81
Revisions
76
Growth
75
Momentum
48
Size
36
Issuance
10

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26BCRXHigh $32Median $17Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $11Median $17High $32

The green dot is the last close — the median target sits +109.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Sept 2026RBC CapitalDowngradeSector Perform$13 → $11
8 Sept 2026NeedhamReiteratesBuy$16
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026RBC CapitalMaintainsOutperform$14 → $13
6 Aug 2026WedbushMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform$21 → $20
13 July 2026JP MorganReinstatesNeutral$12
7 July 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform—
30 June 2026Cantor FitzgeraldMaintainsOverweight—
30 June 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026CitizensMaintainsMarket Outperform—
7 May 2026WedbushMaintainsOutperform—
6 May 2026NeedhamMaintainsBuy—
30 Jan 2026RBC CapitalMaintainsOutperform—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025CitizensMaintainsMarket Outperform—
4 Nov 2025BarclaysMaintainsEqual-Weight—
4 Nov 2025NeedhamMaintainsBuy—
15 Oct 2025Cantor FitzgeraldMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BCRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, BioCryst Pharmaceuticals, Inc. returned +0.6% against +17.5% for the S&P 500, dividends included.

BCRX vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Oct 25Jan 26Apr 26Jul 26BCRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+31.9%
Analysts raising
1
Analysts cutting
1
Fundamentals

BioCryst Pharmaceuticals, Inc. (BCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.0×

Cheaper than 63% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
−4.5×

Cheaper than 96% of US stocks

EV / EBITDA
5.9×

Cheaper than 51% of US stocks

Growth & margins
Revenue growth (YoY)
33.6%

Higher than 80% of US stocks

Earnings growth (YoY)
1441.7%

Higher than 98% of US stocks

Gross margin
98.2%

Higher than 99% of US stocks

Operating margin
45.1%

Higher than 94% of US stocks

Net margin
−40.9%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−221.4%

Higher than 7% of US stocks

Return on assets
52.9%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioCryst Pharmaceuticals, Inc. (BCRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioCryst Pharmaceuticals, Inc. has a market value of $2.1B and an enterprise value of $2.6B.

  • Revenue in the twelve months to 30 June 2026: $940.6M. The latest quarter grew 33.6% year on year.

  • Net income over the same four quarters: −$384.7M, a −40.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.50.

  • Free cash flow in the twelve months to 30 June 2026: $373.4M.

  • Shares outstanding: 255.3M.

  • Trailing P/E: 7.0×; forward P/E: 8.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioCryst Pharmaceuticals, Inc. employs 435 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

BCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BCRXBioCryst Pharmaceuticals, Inc.$2.1B
87
ALVOAlvotech$2.1B
29
BHCBausch Health Cos., Inc.$2.2B
96
PRGOPerrigo Co. Plc$1.9B
76
TRLVTrulieve Cannabis Corp.$2.2B
83
PBHPrestige Consumer Healthcare, Inc.$2.3B
58
SUPNSupernus Pharmaceuticals, Inc.$2.4B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioCryst Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCRX news & analysis

BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity

Seeking Alpha · 11 Sept 2026neutral

BioCryst Pharmaceuticals' shares remain under pressure, though Orladeyo revenue rose 6.7% quarter-over-quarter to $158.2 million in the second quarter. The company's royalty financing obligations also declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.

Why it matters — BCRX watchers would care because recent operating performance shows revenue growth and a reduction in financing obligations even as the share price remains under pressure.

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

MarketBeat · 6 Sept 2026neutral

The White House expanded its most-favored-nation drug pricing agreements, adding nine more manufacturers for a total of 26 companies covering 89% of the branded drug market, while healthcare investors have shown little reaction to the news.

Why it matters — Broader government drug pricing agreements could affect pricing dynamics across the branded pharmaceutical sector where BioCryst operates.

BioCryst to Present at Upcoming Investor Conference

GlobeNewsWire · 1 Sept 2026neutral

BioCryst Pharmaceuticals announced it plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.

Why it matters — The upcoming conference presentation gives BioCryst a platform to share updates with the investment community, which BCRX watchers may follow for company developments.

Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 31 Aug 2026neutral

Zacks Investment Research compared BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) to the broader medical sector in a year-to-date performance review.

Why it matters — BCRX watchers would care about this comparison because it positions the company's stock performance relative to a direct peer and its sector.

BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve

Seeking Alpha · 28 Aug 2026positive

BioCryst Pharmaceuticals is evolving into a dual-product hereditary angioedema (HAE) franchise targeting both oral and injectable prophylactic preferences. The ORLADEYO profit engine supports pipeline funding, with Q2 2026 revenue reaching $218.3M and strong gross margins, while the navenibart acquisition aims to capture injectable-preferring HAE patients using existing commercial infrastructure.

Why it matters — A BCRX watcher would care because the company is broadening its HAE portfolio beyond ORLADEYO while generating positive cash flow, which could expand its patient reach and strengthen customer retention through operating leverage.

FAQ

Frequently asked questions about BCRX stock

What is the BCRX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $11 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCRX stock a buy right now?

Of the 11 analysts covering BioCryst Pharmaceuticals, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCryst Pharmaceuticals, Inc. 87 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCRX?

As at 12 Sept 2026, BioCryst Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will BCRX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +109.4% from the last close, and Ticker Nerd's factor model ranks BioCryst Pharmaceuticals, Inc. 87 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCRX stock forecast for 2030?

No analyst covering BioCryst Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $32 over the next 12 months.

How has BCRX stock performed over the past year?

BioCryst Pharmaceuticals, Inc. returned +0.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE).

What is the latest news on BCRX?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity". BioCryst Pharmaceuticals' shares remain under pressure, though Orladeyo revenue rose 6.7% quarter-over-quarter to $158.2 million in the second quarter. The company's royalty financing obligations also declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.

Company

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy used to help prevent HAE attacks, alongside RAPIVAB, an injectable antiviral medicine used in the treatment of influenza in the United States. The company also supports a broader rare-disease pipeline built around oral small-molecule and protein-based therapeutics designed to address difficult-to-treat conditions. BioCryst Pharmaceuticals serves patients, physicians, and healthcare systems through specialty pharmaceutical products aimed at chronic disease management and acute treatment needs. Headquartered in Durham, North Carolina, BioCryst Pharmaceuticals plays a focused role in the rare-disease market by combining commercial medicines with targeted drug development expertise.

CEO Mr. Charles K. Gayer · 435 employees · United States · https://www.biocryst.com